Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991

被引：0

作者：

Sheppard, Karen E. ^{[1
]}

Foo, Allen ^{[1
]}

Young, Richard ^{[1
]}

Waldeck, Kelly ^{[1
]}

Pearson, Richard ^{[1
]}

McArthur, Grant ^{[1
]}

Christensen, James ^{[2
]}

机构：

[1] Peter MacCallum Canc Ctr, East Melbourne, Australia

[2] Pfizer Oncol, Global Res & Dev, San Diego, CA USA

来源：

CANCER RESEARCH | 2013年 / 73卷 / 08期

关键词：

D O I：

10.1158/1538-7445.AM2013-3416

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3416

引用

页数：1

共 50 条

[1] Clinical significance of genomic alterations of the CDK4-pathway and sensitivity to the CDK4 inhibitor PD 0332991 in melanoma
McArthur, Grant A.
Young, Richard J.
Sheppard, Karen E.
Mar, Victoria
Waldeck, Kelly
Fox, Stephen B.
Kelleher, Fergal C.
Liu, Wendy
Dobrovic, Alexander
Pearson, Richard
Kelly, John
Christensen, James G.
Randolph, Sophia
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[2] Combination of CDK4/6 inhibitor PD-0332991 with standard chemotherapy is synergistic in RB high pancreatic cancer
Chou, A.
Steinmann, A.
Froio, D.
Drury, A.
Wohl, D.
Chin, V.
Nagrial, A.
Gill, A.
Pajic, M.
EUROPEAN JOURNAL OF CANCER, 2016, 61 : S182 - S182
[3] Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma
Dickson, Mark Andrew
Keohan, Mary Louise
Tap, William D.
Antonescu, Cristina
Landa, Jonathan
Qin, Li-Xuan
Dohrenwend, Eric Gerard
Rathbone, Dustin
Ustoyev, Yelena
Condy, Mercedes M.
Singer, Samuel
Schwartz, Gary K.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[4] PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma
Barton, Kelly L.
Misuraca, Katherine
Cordero, Francisco
Dobrikova, Elena
Min, Hooney D.
Gromeier, Matthias
Kirsch, David G.
Becher, Oren J.
PLOS ONE, 2013, 8 (10):
[5] In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours
Schoos, Alexandra
Knab, Vanessa M.
Gabriel, Cordula
Tripolt, Sabrina
Wagner, Daniela A.
Bauder, Barbara
Url, Angelika
Fux, Daniela A.
VETERINARY AND COMPARATIVE ONCOLOGY, 2019, 17 (04) : 507 - 521
[6] PD-0332991, A CDK4/6 INHIBITOR, SIGNIFICANTLY PROLONGS SURVIVAL IN A GENETICALLY ENGINEERED MOUSE MODEL OF BRAINSTEM GLIOMA
Barton, Kelly
Misuraca, Katie
Cordero, Francisco
Dobrikova, Elena
Min, Hooney
Gromeier, Matthias
Kirsch, David
Becher, Oren
NEURO-ONCOLOGY, 2013, 15 : 38 - 38
[7] Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
Bollard, Julien
Miguela, Veronica
de Galarreta, Marina Ruiz
Venkatesh, Anu
Bian, C. Billie
Roberto, Mark P.
Tovar, Victoria
Sia, Daniela
Molina-Sanchez, Pedro
Nguyen, Christie B.
Nakagawa, Shigeki
Llovet, Josep M.
Hoshida, Yujin
Lujambio, Amaia
GUT, 2017, 66 (07) : 1286 - 1296
[8] A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991
O'Dwyer, P. J.
LoRusso, P.
DeMichele, A.
Gupta, V.
Barbi, A.
Dials, H.
Chen, I.
Courtney, R.
Wilner, K.
Schwartz, G. K.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[9] RETRACTED: Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells (Retracted Article)
Liu, Yu
Zhao, Yan
Han, Chongxu
Ren, Chuanli
COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2022, 2022
[10] The CDK4 inhibitor PD-0332991 enhances TGF-\#946; signaling and suppresses growth in human hepatocellular cancer cells
El Zouhairi, Majed
Yang, Shaoxian
Said, Anan
Kim, Sang
Baek, Hae Jung
Kang, Anthony
Mishra, Bibhuti
Reddy, Premkumar
Mishra, Lopa
Pishvaian, Michael
CANCER RESEARCH, 2009, 69

← 1 2 3 4 5 →